Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
Pharmacogenomics and Personalized Medicine
|
February 10, 2016
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Meagan B Myers
Personalized Medicine
|
November 22, 2016
<i>KRAS</i> mutant tumor subpopulations can subvert durable responses to personalized cancer treatments
Barbara L Parsons, Meagan B Myers
Discovery Medicine
|
May 3, 2013
Personalized cancer treatment and the myth of KRAS wild-type colon tumors
Barbara L Parsons, Meagan B Myers
Methods in Molecular Biology (Clifton, N.J.)
|
April 11, 2023
A Brief Practical Guide to PCR
Page B McKinzie, Meagan B Myers
Environmental and Molecular Mutagenesis
|
July 30, 2017
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
Barbara L Parsons, Karen L McKim, Meagan B Myers
Biotechniques
|
October 27, 2009
Using phiX174 DNA as an exogenous reference for measuring mitochondrial DNA copy number
Meagan B Myers, Roberta A Mittelstaedt, Robert H Heflich
Molecular Carcinogenesis
|
August 30, 2012
A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
Meagan B Myers, Karen L McKim, Barbara L Parsons
Personalized Medicine
|
March 1, 2015
Low-frequency <i>KRAS</i> mutations are prevalent in lung adenocarcinomas
Meagan B Myers, Karen L McKim, Fanxue Meng, et al.
Expert Review of Molecular Diagnostics
|
August 1, 2012
Hotspot oncomutations: implications for personalized cancer treatment
Meagan B Myers, Yiying Wang, Karen L McKim, et al.
Mutation Research
|
April 26, 2003
Accumulation of point mutations in mitochondrial DNA of aging mice
Magomed Khaidakov, Robert H Heflich, Mugimane G Manjanatha, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
Pharmacogenomics and Personalized Medicine
|
February 10, 2016
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Meagan B Myers
Personalized Medicine
|
November 22, 2016
<i>KRAS</i> mutant tumor subpopulations can subvert durable responses to personalized cancer treatments
Barbara L Parsons, Meagan B Myers
Discovery Medicine
|
May 3, 2013
Personalized cancer treatment and the myth of KRAS wild-type colon tumors
Barbara L Parsons, Meagan B Myers
Methods in Molecular Biology (Clifton, N.J.)
|
April 11, 2023
A Brief Practical Guide to PCR
Page B McKinzie, Meagan B Myers
Environmental and Molecular Mutagenesis
|
July 30, 2017
Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
Barbara L Parsons, Karen L McKim, Meagan B Myers
Biotechniques
|
October 27, 2009
Using phiX174 DNA as an exogenous reference for measuring mitochondrial DNA copy number
Meagan B Myers, Roberta A Mittelstaedt, Robert H Heflich
Molecular Carcinogenesis
|
August 30, 2012
A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid
Meagan B Myers, Karen L McKim, Barbara L Parsons
Personalized Medicine
|
March 1, 2015
Low-frequency <i>KRAS</i> mutations are prevalent in lung adenocarcinomas
Meagan B Myers, Karen L McKim, Fanxue Meng, et al.
Expert Review of Molecular Diagnostics
|
August 1, 2012
Hotspot oncomutations: implications for personalized cancer treatment
Meagan B Myers, Yiying Wang, Karen L McKim, et al.
Mutation Research
|
April 26, 2003
Accumulation of point mutations in mitochondrial DNA of aging mice
Magomed Khaidakov, Robert H Heflich, Mugimane G Manjanatha, et al.
Page
of 4